The Massachusetts Appeals Court has affirmed the dismissal of a woman’s claims that she was injured by knee-pain injections manufactured by biotech company Genzyme.

Patricia M. Dunn filed the suit in state court arguing that Genzyme’s product Synvisc-One is regulated as a Class III supplement by the Medical Device Amendments and subject to pre-market approval.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]